Menu
No results found.
Weekly Share Price & Valuation Overview
Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Revenue growth ≥10% indicates solid top-line momentum.
- Earnings growth ≥10% supports improving profitability trajectory.
- Quick ratio <0.8 — tight near-term liquidity without inventory.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- USD 410.41M
- Enterprise Value Operating value: market cap + total debt − cash.
- USD 925.44M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- USD 268.12M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- USD 123.96M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- USD -35.34M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- USD 1.37
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -0.54
- Shares Outstanding
- 200.20M
- Float Shares
- 199.76M
- Implied Shares Outstanding
- 200.20M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
8.61%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
-13.18%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
46.23%
- Profit Margin (TTM) Net income ÷ revenue over the last twelve months (reconciled when possible).
-
-38.80%
- ROA Return on assets: net income ÷ total assets.
-
-6.34%
- Revenue Growth Strong Year-over-year revenue growth.
-
11.60%
- Earnings Growth (YoY) Strong Year-over-year earnings growth.
-
30.00%
- Quick Ratio Liquid current assets ÷ current liabilities (ex-inventory).
- 0.65
- Total Cash Cash and equivalents.
- USD 86.06M
- Total Debt Short + long-term interest-bearing debt.
- USD 598.18M
- Net Debt Total debt − cash (negative = net cash).
- USD 512.12M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- -16.93
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- USD -124.33M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- USD -120.30M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
-46.37%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
-44.87%
- Cash Conversion (OpCF/EBITDA)
- 3.52
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.